Stock 3KY HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hansoh Pharmaceutical Group Company Limited Deutsche Boerse AG

Equities

3KY

KYG549581067

Market Closed - Deutsche Boerse AG
Other stock markets
 06:59:01 28/06/2024 pm IST 		5-day change 1st Jan Change
1.88 EUR -4.57% Intraday chart for Hansoh Pharmaceutical Group Company Limited -3.59% +14.63%
14/06 Hansoh Pharmaceutical Slashes Conversion Price of Convertible Bonds MT
30/04 Hansoh Pharmaceutical’s 2023 Profit Up 27% MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED Stock Hansoh Pharmaceutical Group Company Limited
+14.63% 1.25TCr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 82TCr
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 35TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 33TCr
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 30TCr
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 24TCr
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 23TCr
A+
NOVARTIS AG Stock Novartis AG
+13.31% 22TCr
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 17TCr
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 16TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 3692 Stock
  4. 3KY Stock
  5. Ratings Hansoh Pharmaceutical Group Company Limited